Table 2.
Reasons underlying unwillingness or hesitation to be vaccinated against pandemic H1N1 (n, %)
| Reasons of unwillingness or hesitation | Will not be vaccinated | Indecisive | Total |
|---|---|---|---|
| Possible side effects | 267 (74.8) | 251 (82.0) | 518 (78.1) |
| Lack of comprehensive field evaluation before marketing | 266 (74.5) | 241 (78.8) | 507 (76.5) |
| Implementation in our country before wide implementation in other countries | 199 (55.9) | 184 (60.1) | 383 (57.9) |
| Vaccines which will be administered here are different than the vaccines in the US | 153 (42.9) | 137 (44.9) | 290 (43.8) |
| Do not have trust in the effectiveness of the vaccine | 157 (44.0) | 114 (37.3) | 271 (40.9) |
| Do not trust Ministry of Health's practices | 147 (41.2) | 104 (34.0) | 251 (37.9) |
| Due to the risk of acquiring H1N1 following vaccination | 71 (19.9) | 66 (21.6) | 137 (20.7) |
| The disease is mild | 59 (16.5) | 34 (11.1) | 93 (14.0) |
| Contracting the disease is safer | 34 (9.5) | 13 (4.2) | 47 (7.1) |
| Other | 30 (8.4) | 15 (4.9) | 45 (6.8) |